公开(公告)号：US20160083478A1

公开(公告)日：2016-03-24

申请号：US14729798

申请日：2015-06-03

Applicant: Mark I. Greene ,  Donald M. O'Rourke ,  Ramachandran Murali ,  Byeong Woo Park

Inventor： Mark I. Greene ,  Donald M. O'Rourke ,  Ramachandran Murali ,  Byeong Woo Park

IPC: C07K16/32 ,  A61K45/06 ,  A61N5/10 ,  A61K39/395

CPC classification number: C07K16/32 ,  A61K38/1709 ,  A61K39/39558 ,  A61K45/06 ,  A61K48/00 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/572 ,  A61N5/10 ,  C07K14/71 ,  C07K2317/24 ,  C07K2317/73 ,  A61K2300/00

Abstract: Methods of treating an individual who has an erbB protein mediated tumor is disclosed. Methods of preventing erbB protein mediated tumors in an individual are disclosed. The methods comprise administering to the individual a nucleic acid molecule that encodes a protein that dimerizes with an erbB protein and that is deficient in tyrosine kinase activity. Composition that comprise such nucleic acid molecules including pharmaceutical compositions are disclosed.

公开(公告)号：US08728479B2

公开(公告)日：2014-05-20

申请号：US13262060

申请日：2010-03-31

Applicant: Mark I. Greene ,  Hongtao Zhang ,  Xiaomin Song ,  Ramachandran Murali ,  Masahide Tone

Inventor： Mark I. Greene ,  Hongtao Zhang ,  Xiaomin Song ,  Ramachandran Murali ,  Masahide Tone

IPC: A61K39/00

CPC classification number: A61K38/16 ,  A61K49/00 ,  C07K1/22 ,  C07K14/70596 ,  C07K16/2896 ,  C07K19/00 ,  C07K2319/30 ,  G01N33/53

Abstract: Disclosed herein are recombinant protein scaffolds and recombinant multifunctional protein scaffolds for use in producing antigen-binding proteins In addition, nucleic acids encoding such recombinant protein scaffolds, recombinant multifunctional protein scaffolds, and antigen-binding proteins are provided Vectors and cells useful for expression of the described proteins are also provided, as are methods of use.

Abstract translation: 本文公开了用于产生抗原结合蛋白的重组蛋白质支架和重组多功能蛋白质支架。此外，提供了编码这种重组蛋白质支架的核酸，重组多功能蛋白质支架和抗原结合蛋白。用于表达 还提供了所描述的蛋白质，以及使用方法。

公开(公告)号：US20130137774A1

公开(公告)日：2013-05-30

申请号：US13700915

申请日：2011-05-26

Applicant: Mark I. Greene ,  Ramachandran Murali ,  Hongtao Zhang

Inventor： Mark I. Greene ,  Ramachandran Murali ,  Hongtao Zhang

IPC: A61K31/165 ,  A61K45/06

CPC classification number: A61K31/165 ,  A61K45/06 ,  A61K51/04 ,  G01N33/574 ,  G01N2333/71

Abstract: This application describes pharmaceutical compositions, commercial packages, and methods for inhibiting cell proliferative disorders, especially those disorders, including Her2 related cancers, characterized by overactivity and/or inappropriate activity of a receptor tyrosine kinase, and methods for imaging an HER-2 expressing tumor.

Abstract translation: 本申请描述了用于抑制细胞增殖性疾病的药物组合物，商业包装和方法，特别是包括Her2相关癌症的那些疾病，其特征在于受体酪氨酸激酶的过度活跃和/或不适当的活性，以及​​用于成像表达HER-2的肿瘤的方法 。

公开(公告)号：US20120108559A1

公开(公告)日：2012-05-03

申请号：US13144568

申请日：2010-01-07

Applicant: Ramachandran Murali ,  Mark I. Greene

Inventor： Ramachandran Murali ,  Mark I. Greene

IPC: A61K31/585 ,  C07J17/00 ,  A61P19/08

CPC classification number: A61K31/585

Abstract: Methods and pharmaceutical compositions utilizing compounds of Formula II: for inhibiting osteoclastogenesis and the activity of osteoclasts in patients.

Abstract translation: 利用式II化合物的方法和药物组合物：用于抑制破骨细胞形成和破骨细胞在患者体内的活性。

公开(公告)号：US20110020332A1

公开(公告)日：2011-01-27

申请号：US12804419

申请日：2010-07-21

Applicant: Mark I. Greene ,  Makoto Matsumata ,  Jeffrey Drebin

Inventor： Mark I. Greene ,  Makoto Matsumata ,  Jeffrey Drebin

IPC: A61K39/395 ,  A61P35/00

CPC classification number: C07K16/32 ,  A61K38/00 ,  A61K2039/505

Abstract: Methods of preventing the transformation of a normal cell into a tumor cell that has p185 on its surface are disclosed. The methods comprise administering an antibody which specifically binds to p185. Methods of preventing the transformation of a normal cell into a tumor cell that has p185 on its surface in an individual at high risk of developing tumors are disclosed.

Abstract translation: 公开了防止正常细胞向其表面具有p185的肿瘤细胞转化的方法。 所述方法包括施用特异性结合p185的抗体。 公开了防止正常细胞转化成肿瘤细胞的方法，所述肿瘤细胞在具有高发展肿瘤风险的个体的表面上具有p185。

公开(公告)号：US07781566B2

公开(公告)日：2010-08-24

申请号：US12625650

申请日：2009-11-25

Applicant: Mark I. Greene ,  Ramachandran Murali ,  Hongtao Zhang ,  Mark Richter ,  Alan Berezov ,  Qingdu Liu ,  Jinqiu Chen

Inventor： Mark I. Greene ,  Ramachandran Murali ,  Hongtao Zhang ,  Mark Richter ,  Alan Berezov ,  Qingdu Liu ,  Jinqiu Chen

IPC: A61K38/00 ,  C07K14/00

CPC classification number: C07K14/71 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0011 ,  A61K47/48238 ,  A61K47/4833 ,  A61K47/48384 ,  A61K47/48407 ,  A61K47/48507 ,  A61K47/62 ,  A61K47/646 ,  A61K47/6803 ,  A61K47/6809 ,  A61K47/6835 ,  A61K51/10 ,  C07K7/06 ,  C07K7/08 ,  C07K14/7151 ,  C07K14/82

Abstract: Peptides, mimetics and antibodies of erbB, TNF, and IgSF receptors and pharmaceutical compositions comprising the same are described. Methods of using such antibodies, peptides, and mimetics in therapeutic, prophylactic, imaging and diagnostic applications are disclosed.

Abstract translation: 描述了erbB，TNF和IgSF受体的肽，模拟物和抗体以及包含其的药物组合物。 公开了在治疗，预防，成像和诊断应用中使用这些抗体，肽和模拟物的方法。

公开(公告)号：US20100189649A1

公开(公告)日：2010-07-29

申请号：US12651527

申请日：2010-01-04

Applicant: Mark I. Greene ,  Hongtao Zhang ,  Mark Richter ,  Ramachandran Murali

Inventor： Mark I. Greene ,  Hongtao Zhang ,  Mark Richter ,  Ramachandran Murali

IPC: A61K39/395 ,  C07K16/00 ,  A61K49/00 ,  A61P35/00

CPC classification number: C07K14/71 ,  A61K38/00 ,  A61K39/00 ,  A61K47/62 ,  A61K47/646 ,  C07K14/7151 ,  C07K14/82

Abstract: Antibodies which bind to activated members of the erbB, TNF, and IgSF family of receptors and pharmaceutical compositions comprising the same are disclosed. Peptides and mimetics of erbB, TNF, and IgSF receptors and pharmaceutical compositions comprising the same are also described. Methods of using such antibodies, peptides, and mimetics in tumor therapeutic, prophylactic, imaging and diagnostic applications are disclosed.

Abstract translation: 公开了结合erbB，TNF和IgSF受体家族的活化成员的抗体和包含其的药物组合物的抗体。 还描述了erbB，TNF和IgSF受体的肽和模拟物以及包含其的药物组合物。 公开了在肿瘤治疗，预防，成像和诊断应用中使用这些抗体，肽和模拟物的方法。

公开(公告)号：US20100040618A1

公开(公告)日：2010-02-18

申请号：US12589053

申请日：2009-10-15

Applicant: Mark I. Greene ,  Makoto Katsumata ,  Jeffrey Drebin

Inventor： Mark I. Greene ,  Makoto Katsumata ,  Jeffrey Drebin

IPC: A61K39/395

CPC classification number: C07K16/32 ,  A61K38/00 ,  A61K2039/505

Abstract: Methods of preventing the transformation of a normal cell into a tumor cell that has p185 on its surface are disclosed. The methods comprise administering an antibody which specifically binds to p185. Methods of preventing the transformation of a normal cell into a tumor cell that has p185 on its surface in an individual at high risk of developing tumors are disclosed.

Abstract translation: 公开了防止正常细胞向其表面具有p185的肿瘤细胞转化的方法。 所述方法包括施用特异性结合p185的抗体。 公开了防止正常细胞转化成肿瘤细胞的方法，所述肿瘤细胞在具有高发展肿瘤风险的个体的表面上具有p185。

公开(公告)号：US20090306030A1

公开(公告)日：2009-12-10

申请号：US12488868

申请日：2009-06-22

Applicant: Mark I. Greene ,  Ramachandran Murali ,  Masahiko Kinosaki

Inventor： Mark I. Greene ,  Ramachandran Murali ,  Masahiko Kinosaki

IPC: A61K31/585 ,  A61K31/03 ,  A61K31/565 ,  A61K31/58 ,  A61P19/00

CPC classification number: C07K14/70575 ,  A61K31/00 ,  A61K31/03 ,  A61K31/235 ,  A61K31/565 ,  A61K31/585 ,  A61K38/1709 ,  C07K5/1013 ,  C07K5/1016 ,  C07K5/1021

Abstract: Methods of inhibiting osteoclastogenesis and the activity of osteoclasts are disclosed. Methods of treating patients who have diseases characterized bone loss are disclosed. According to the methods, an amount of a TRANCE/RANK inhibitor effective to inhibit osteoclastogenesis is administered to the patient. Pharmaceutical compositions which comprise TRANCE/RANK inhibitor in an amount effective to inhibit osteoclastogenesis. Methods of modulating dendritic cell maturation, T cell proliferation, and/or CD40 receptor systems in an individual are disclosed. The methods comprise the step of administering to the individual an amount of a TRANCE/RANK inhibitor effective to modulating dendritic cell maturation, T cell proliferation, and/or CD40 receptor systems.

Abstract translation: 公开了抑制破骨细胞发生的方法和破骨细胞的活性。 公开了治疗具有骨丢失特征的患者的方法。 根据该方法，向患者施用一定量的有效抑制破骨细胞发生的TRANCE / RANK抑制剂。 含有有效抑制破骨细胞发生量的TRANCE / RANK抑制剂的药物组合物。 公开了调节个体中树突状细胞成熟，T细胞增殖和/或CD40受体系统的方法。 所述方法包括向个体施用一定量的有效调节树突状细胞成熟，T细胞增殖和/或CD40受体系统的TRANCE / RANK抑制剂的步骤。

公开(公告)号：US20090286737A1

公开(公告)日：2009-11-19

申请号：US10119288

申请日：2002-04-08

Applicant: Mark I. Greene ,  Ramachandran Murali ,  Alan Berezov ,  Qingdu Liu ,  Jinqiu Chen

Inventor： Mark I. Greene ,  Ramachandran Murali ,  Alan Berezov ,  Qingdu Liu ,  Jinqiu Chen

IPC: A61K38/10 ,  C07K7/08

CPC classification number: C07K14/71 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0011 ,  A61K47/48238 ,  A61K47/4833 ,  A61K47/48384 ,  A61K47/48407 ,  A61K47/48507 ,  A61K47/62 ,  A61K47/646 ,  A61K47/6803 ,  A61K47/6809 ,  A61K47/6835 ,  A61K51/10 ,  C07K7/06 ,  C07K7/08 ,  C07K14/7151 ,  C07K14/82

Abstract: Peptides, mimetics and antibodies of erbB, TNF, and IgSF receptors and pharmaceutical compositions comprising the same are described. Methods of using such antibodies, peptides, and mimetics in therapeutic, prophylactic, imaging and diagnostic applications are disclosed.

Abstract translation: 描述了erbB，TNF和IgSF受体的肽，模拟物和抗体以及包含其的药物组合物。 公开了在治疗，预防，成像和诊断应用中使用这些抗体，肽和模拟物的方法。